Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled monotherapy study of milnacipran in fibromyalgia
2005-003137-40Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibromyalgia (FM) comparing Milnacipran 200 mg/day with Placebo (2 arms). Primary endpoint: Primary composite efficacy criterion. Started Aug 2005; status: completed.
02
Drugs
milnacipran
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2005-003137-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003137-40.